Emkay Global maintains a 'Buy' rating on Sun Pharma after the US Court of Appeals vacates the injunction against Leqselvi's ...

Dilip Shanghvi had said in February that the judgment was crucial for Sun Pharma's future course of action on this drug launch.

After falling 17 per cent since the start of the year to its March lows, the stock of the country's largest pharmaceutical ...

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

According to market estimates, Leqselvi is projected to contribute $90 million to Sun Pharma's sales in FY26, and $125 ...

The US Court of Appeals for the Federal Circuit vacated a preliminary injunction on Leqselvi’s launch, lifting restrictions on the launch on April 9, Sun Pharma said in a regulatory filing.

Emkay Global Financial Services, in a client note, described the development as “materially positive,” as it removes a key ...

Delhi: In a major relief to Sun Pharmaceutical Industries Ltd, the U.S. Court of Appeals for the Federal Circuit has vacated ...

Sun Pharmaceuticals Industries on Thursday said the US Court of Appeals for the Federal Circuit has ruled in favour of the company and vacated its preliminary injunction of delaying the launch of ...

Sun Pharma stock rose more than 5 per cent intraday on Friday, April 11, after the company got a favorable order from a US ...

Sun Pharma had been locked in a patent infringement litigation with Incyte Corporation over LEQSELVI (deuruxolitinib).